LGC's capabilities and experience cover recombinant proteins, vaccines, blood products, monoclonal antibodies, oligonucleotides, gene therapy products and more. Development and validation of bioanalytical assays to support your biopharmaceutical development programme, whether it be Pharmacokinetic (PK), Anti-Drug-Antibody (ADA), Neutralising Antibodies (nAbs) or Pharmacodynamic (PD) is core to the LGC business.
LGC's bioanalytical services for biopharmaceuticals include: